leveraging the holistic benefits of biosimilars in Europe – part 2: how payers can safeguard the future of a healthy biosimilar market environment-Reference-Cited by-同舟云学术

leveraging the holistic benefits of biosimilars in Europe – part 2: how payers can safeguard the future of a healthy biosimilar market environment

Published:2024-01-29 Issue: Volume: Page:
ISSN:1473-7167
Container-title:Expert Review of Pharmacoeconomics & Outcomes Research
language:en
Short-container-title:Expert Review of Pharmacoeconomics & Outcomes Research

Author:

Mestre-Ferrandiz Jorge¹,Czech Marcin²,Smolen Josef S.³,Cornes Paul⁴,Aapro Matti S.⁵,Danese Silvio⁶,Deitch Stephen⁷,Tyldsley Hannah⁷,Foster Will⁷,Shah Pooja⁸,Latymer Mark⁹,Vulto Arnold G.¹⁰

Affiliation:

1. Universidad Carlos III, Madrid, Spain

2. Department of Pharmacoeconomics, Institute of Mother and Child, Warsaw, Poland

3. Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria

4. Comparative Outcomes Group, Bristol, UK

5. Cancer Center, Clinique de Genolier, Vaud, Switzerland

6. Gastroenterology and Endoscopy, IRCCS Ospedale San Raffaele and University Vita-Salute San Raffaele, Milan, Italy

7. Charles River Associates, London, UK

8. Pfizer, Collegeville, PA, USA

9. Pfizer, Sandwich, UK

10. Hospital Pharmacy, Erasmus University Medical Center, Rotterdam, Netherlands

Funder

Pfizer

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Health Policy,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737167.2024.2310684

Reference62 articles.

1. Selected references are highlighted as being of interest .

2. What is the future of targeted therapy in rheumatology: biologics or small molecules?;Mócsai A;BMC Med

3. European Medicines Agency. Biosimilar medicines: Overview 2023 [cited 2023 Feb 2]. Available from: https://www.ema.europa.eu/en/human-regulatory/overview/biosimilar-medicines-overview

4. Bioequivalence studies with anti-TNF biosimilars

5. Bioequivalence of Biosimilar Tumor Necrosis Factor-α Inhibitors Compared With Their Reference Biologics